7 replies to this topic

[stefan_001]

https://www.scienced...872931217301011

Conclusion: Chronic NIAGEN supplementation lowers SBP in pHTN older
adults and reduces aortic stiffness, independent of baseline blood pressure
status.

[stefan_001]

Suspect this is one of the findings of this trial:

 

https://clinicaltria...riboside&rank=2

 

So result of 6 weeks of supplementation in n=30 HUMANS!! Not mice as some like to always remind......Real improvement, no buts and if's

Edited by stefan_001, 09 December 2017 - 09:43 PM.

[able]

Sci-Hub came up with part of this paper, but not complete.  Here’s what I found:

 

Nicotinamide riboside supplementation reduces aortic stiffness and blood pressure in middle-aged and older adults

 

"Purpose: Regular calorie restriction (CR) improves endothelial function and lowers aortic stiffness in older mice and humans; however, adherence to sus- tained CR remains poor, and possibly unsafe in normal weight older adults. Nicotinamide adenine dinucleotide (NAD+) is an important signaling molecule involved in the beneficial effects of CR and we have recently demonstrated that boosting NAD+ reverses these measures of arterial aging in older mice. The purpose of this study was to determine if supplementation with nicotin- amide riboside (NIAGEN"; ChromaDex, Inc.), a naturally occurring precursor to NAD+, would similarly improve vascular function with aging in humans. Methods: Healthy middle-aged and older adults (65 ` 2 yrs, n Z 24) received oral NIAGEN" (500 mg, 2x/day) and placebo capsules for six weeks each in a randomized, placebo-controlled crossover study. Blood pressure (BP), aortic stiffness (carotid-femoral pulse wave velocity [PWV]), and endothelial func- tion, (brachial artery flow-mediated dilation [FMD]), were measured at the end of each intervention phase. 

 

Results: NIAGEN" safely and effectively raised circulating levels of NAD+ and related metabolites. Although no effect was observed on endothelial func- tion, NIAGEN" significantly lowered PWV as well as systolic (SBP) and dia- stolic blood pressure (DBP) in all subjects (P < 0.05). When separated by baseline BP status, the BP-lowering effect of NIAGEN" was observed in pre-hypertensive (pHTN, n Z 13) but not normotensive (N Z 11) individuals (P < 0.01). Interestingly, NIAGEN" was lowered in all subjects regardless of baseline BP status. 

Conclusion: Chronic NIAGEN supplementation lowers SBP in pHTN older adults and reduces aortic stiffness, independent of baseline blood pressure status. "

 

 

 

 

So they ended up with 24 participants, who received 500 Mg of NR twice per day.

11 who had normal BP saw no effect on BP, but improved Aortic stiffness.

14 who were pre-hypertensive did have decrease BP.   

Good to see some improvement from a 6 week trial, and will be interested to see how much the decrease is.  

 

 

The secondary measures they studied are below- Sounds like they didn't see significant improvement in other areas like cognition, mobility, or inflammation.

 

Anyone have access to the full paper?

 

 

Secondary Outcome Measures:

• Endothelium Dependent Dilation [ Time Frame: 6 weeks ]
  Brachial Artery Flow-Mediated Dilation (FMD)
• Arterial Stiffness [ Time Frame: 6 weeks ]
  Aortic Pulse Wave Velocity (PWV)
• Cognitive Function [ Time Frame: 6 weeks ]
  NIH Toolbox Cognitive Function Battery
• Motor Function [ Time Frame: 6 weeks ]
  NIH Toolbox Motor Function Battery
• Systemic markers of oxidative stress and inflammation [ Time Frame: 6 weeks ]
  Assessment of plasma C-reactive protein (CRP) and circulating and mononuclear cell-derived cytokine and antioxidant expression.

 

Edited by able, 10 December 2017 - 04:43 PM.

[stefan_001]

I don't think the paper is ready, this was from a memo from a conference:
Joint Session with LATAM and North American Artery, NAA1.


Also looking at the name its too early to conclude that the other outcomes didnt show positives. I don't think the audience is the correct one.

[stefan_001]

My take is that they took it there to get feedback on the significance or lack thereof

[able]

Yeah, I noticed it was from the Latam cardiovascular conference, and  the article was published in "artery research", where they would just write about the cv benefits.  

 

I see that was published Oct 14, so hope we get the complete results soon.

 

Will be interesting to see any benefits in mobility, compared to the elysium study, as they were 6 and 8 week duration.

 

Of course, researchers, insiders, and big investors have a good idea what the results show, and likely behind the recent stock increase for Chromadex.

Edited by able, 10 December 2017 - 06:27 PM.

[Michael]

Suspect this is one of the findings of this trial:
 
https://clinicaltria...riboside&rank=2
 
So result of 6 weeks of supplementation in n=30 HUMANS!! Not mice as some like to always remind......Real improvement, no buts and if's

Well, I'd say there's at least one 'if' and at least one 'but.'
 

The "if" is "if the result is replicated in a larger independent trial."

 

The "but" is that in the Elysium Basis trial, 8 weeks of 250 mg of NR plus 50 mg of PT lowered diastolic BP only (3.4 ± 7.1 mmHG — tho' there was a trend toward a similar reduction in systolic),  with no effect on either parameter at 500 mg of NR plus 100 mg of PT (Table S4). In this trial,  125 mg PT twice daily alone was reported to  lower both systolic (−7.8 mmHg) and diastolic (−7.3 mmHg) BP; 100 mg twice daily led to a trend of reduction of SBP and DBP of similar magnitude to that reported for 250 mg of NR plus 50 mg of PT.

[Kirito]

Seems to fit very nicely with this NMN paper: https://www.ncbi.nlm...pubmed/26970090